<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36877">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986621</url>
  </required_header>
  <id_info>
    <org_study_id>Antiplatelet therapy after PCI</org_study_id>
    <nct_id>NCT01986621</nct_id>
  </id_info>
  <brief_title>Identifying Patients at Higher Risk for Periprocedural Myocardial Injury or Infarction Who Might Benefit From More Potent Antiplatelet Therapy Following Elective PCI</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <authority>Germany: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to identify patients at moderate to high risk for peri-procedural
      (type 4) myocardial infarction or injury after after undergoing an elective coronary
      intervention (PCI) as measured by high sensitivity troponin T, who might benefit from more
      potent antiplatelet therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Myocardial infarction or injury</measure>
    <time_frame>Within 48 hours after PCI</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>hsTnT Release After Elective Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Patients undergoing elective PCI</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stable or unknown CAD undergoing elective coronary intervention without
        receiving additional examination, such as biopsy, Ablation or any other procedure that
        could lead to myocardial injury resulting in elevation of the cardiac Troponin.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable or unknown coronary artery disease (CAD)

          -  Elective coronary intervention

          -  Minimum age of 18

        Exclusion Criteria:

          -  Present acute coronary syndrome (ACS)

          -  Age under 18

          -  Pregnancy

          -  Any additional invasive intervention with potential myocardial injury

          -  Non ACS conditions responsible for elevation of cardiac troponin, such as acute
             pulmonary artery embolism, myocarditis or tachycardia.

          -  Procedure related complications leading to troponin elevations (e.g. coronary
             dissection)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haitham Abu Sharar, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evangelos Giannitsis, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haitham Abu Sharar, Dr. med.</last_name>
    <email>haitham.abu-sharar@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evangelos Giannitsis, Prof. Dr.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology - University Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Haitham Abu Sharar</investigator_full_name>
    <investigator_title>Arzt</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
